(lp0
S'Catalyst Pharma  Focused on US Approval for Firdapse Yahoo Finance - Mar 23, 2017 Catalyst has in-licensed rights to Firdapse from BioMarin Pharmaceutical Inc. BMRN for the development and commercialization of the product in the U.S.HC Wainwright Reiterates Buy Rating for Catalyst Pharmaceuticals Inc  - BNB Daily '
p1
aS'The Top Three Holders Of Catalyst Pharmaceuticals, Inc.  Post Analyst - 20 hours ago Catalyst Pharmaceuticals, Inc.  reached 245.1% versus a 1-year low price of $0.51. The stock was last seen 1.15% higher, reaching at $1.76 on Apr. 13, 2017.Enablence Technologies Inc.  EPS Estimated At $0.00; Catalyst ... - High Point ObserverCatalyst Pharmaceuticals Inc  Lifted to Buy at Zacks Investment Research - Community Financial News'
p2
aS'Catalyst Pharmaceuticals  Jumps: Stock Gains 18.2% March 28, 2017 Zacks.com - Mar 28, 2017 Catalyst Pharmaceuticals, Inc.  was a big mover last session, as its shares rose over 18% on the day.'
p3
aS"Catalyst Pharmaceuticals Inc. | $CPRX Stock | Shares Spike Over 20% On ... TickerTV News  - Mar 15, 2017 On Wednesday morning, Catalyst Pharmaceuticals announced that they had positive data following a trial of its treatment for myasthenia gravis.Catalyst Pharma's neuromuscular drug succeeds in study - Channel NewsAsia"
p4
aS'Catalyst Pharmaceuticals Inc.  Pops on Earnings StockNewsUnion - Mar 27, 2017 Coral Gables, FL-based Catalyst Pharmaceuticals Inc.  shares had been struggling to stay at a price above $1.20 between the end of October, 2016 and March 14, 2017.Catalyst Pharmaceuticals, Inc.  Makes It Very Clear Through These Technicals - NY Stock NewsCatalyst Pharmaceuticals, Inc.  shows weekly volitility of 12.11% - The Newburgh Press'
p5
aS"Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting ... Yahoo Finance - Mar 21, 2017 After hours trading showed a continued rise in the company's stock price. Catalyst Pharmaceuticals is a biopharmaceutical company that is currently focused on the development of innovative treatments dealing with rare neuromuscular and neurological&nbsp;..."
p6
aS"Catalyst Pharmaceuticals Inc  Raised to Buy at Zacks Investment Research The Cerbat Gem - Apr 12, 2017 Catalyst Pharmaceuticals logo Catalyst Pharmaceuticals Inc  was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Tuesday.17 institutional investors are raising stakes in Catalyst Pharmaceuticals, Inc ... - Post AnalystAnalysts Offer Predictions for Catalyst Pharmaceuticals Inc's Q1 2017 Earnings ... - Sports Perspectives"
p7
aS'Revenue Approximations Analysis: Catalyst Pharmaceuticals, Inc. , Live ... StockNewsJournal - Mar 22, 2017 ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.'
p8
aS'Price Alert: Catalyst Pharmaceuticals Inc  Stock Nears Resistance ... CML News - Apr 7, 2017 Price Alert: Catalyst Pharmaceuticals Inc  has now crossed into technical strength -- watch the technical oscillators for momentum gaps.'
p9
aS"Investor's Watch List: Catalyst Pharmaceuticals, Inc.  StandardOracle - Apr 7, 2017 Catalyst Pharmaceuticals, Inc.  jumped 2.89 percent and ended the day at $1.78. The Average Volume of the company is 1.15 Million and P/E  ratio is 0, while Forward P/E ratio is 0. Piper Jaffray Upgrade its coverage for ...Catalyst Pharmaceuticals Inc  Shares Gap Up on Earnings Beat - Sports Perspectives"
p10
a.